AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma
Blood Cancer Talks
The Impact of Echelon One on Practice Changes
S1826 was a phase three trial of almost a thousand patients with advanced stage Hodgkin lymphoma who were randomized to receive either six cycles of novolomab plus ABD or brentoxamabplus ABD. The primary endpoint of that study was progression free survival PFS. We just heard at the recent meetings this year that the one year progression free survival was 94% for the noVolomab ABD arm and 86% for BVABD so before we dive in if a patient sees you in clinic this week is that one year PFS result enough to shift your practice? Yeah that's a great question and usually I'm super conservative I'm waiting for it
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode